Chromosome translocations in multiple myeloma.
Reads0
Chats0
TLDR
Oncogenes dysregulated by primary IgH translocations in MM do not appear to confer an anti-apoptotic effect, but instead increase proliferation and/or inhibit differentiation.Abstract:
Multiple myeloma (MM), a malignant tumor of somatically mutated, isotype-switched plasma cells (PC), usually arises from a common benign PC tumor called Monoclonal Gammopathy of Undetermined Significance (MGUS). MM progresses within the bone marrow, and then to an extramedullary stage from which MM cell lines are generated. The incidence of IgH translocations increases with the stage of disease: 50% in MGUS, 60–65% in intramedullarly MM, 70–80% in extramedullary MM, and >90% in MM cell lines. Primary, simple reciprocal IgH translocations, which are present in both MGUS and MM, involve many partners and provide an early immortalizing event. Four chromosomal partners appear to account for the majority of primary IgH translocations: 11q13 (cyclin D1), 6p21 (cyclin D3), 4p16 (FGFR3 and MMSET), and 16q23 (c-maf). They are mediated primarily by errors in IgH switch recombination and less often by errors in somatic hypermutation, with the former dissociating the intronic and 3′ enhancer(s), so that potential oncogenes can be dysregulated on each derivative chromosome (e.g., FGFR3 on der14 and MMSET on der4). Secondary translocations, which sometimes do not involve Ig loci, are more complex, and are not mediated by errors in B cell specific DNA modification mechanisms. They involve other chromosomal partners, notably 8q24 (c-myc), and are associated with tumor progression. Consistent with MM being the malignant counterpart of a long-lived PC, oncogenes dysregulated by primary IgH translocations in MM do not appear to confer an anti-apoptotic effect, but instead increase proliferation and/or inhibit differentiation. The fact that so many different primary transforming events give rise to tumors with the same phenotype suggests that there is only a single fate available for the transformed cell.read more
Citations
More filters
Journal ArticleDOI
Deregulation of c-Myc Confers Distinct Survival Requirements for Memory B Cells, Plasma Cells, and Their Progenitors
TL;DR: The data indicate that the survival requirements for tumor-susceptible PCpre and PCs are distinct and that tumor progression likely develops as PCpre transition to functional PCs when apoptotic pathways such as members of the Bcl-2 family are disabled.
Journal ArticleDOI
Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche
Fotis Asimakopoulos,Chelsea Hope,Michael G. Johnson,Adam Pagenkopf,Kimberly Gromek,Bradley Nagel +5 more
TL;DR: The myeloid-in-myeloma compartment includes myeloma-associated macrophages and granulocytes, dendritic cells, and myELoid-derived-suppressor cells.
Journal ArticleDOI
Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance.
Matthew Ho,Chia Yin Goh,Ashish Patel,Susannah Staunton,Ronan O’Connor,Marc Godeau,Giada Bianchi +6 more
TL;DR: The present review has discussed the current understanding of the role of the BM microenvironment in MM progression and resistance to therapy and discusses novel potential approaches to alter its pro-MM function.
Journal ArticleDOI
Clinical significance of cytogenetics and interphase fluorescence in situ hybridization analysis in newly diagnosed multiple myeloma in Taiwan
S.-Y. Huang,Ming Yao,Jih-Luh Tang,Woei Tsay,F.-Y. Lee,M.-C. Liu,C.-H. Wang,Yee-Chun Chen,M.-C. Shen,Hwei-Fang Tien +9 more
TL;DR: MM CA in patients are similar to those noted in Western countries, and that combined CG and FISH analysis can predict prognosis, and a novel recurrent CA, add(19)(p13), was found in four patients.
Journal ArticleDOI
ANKHD1 regulates cell cycle progression and proliferation in multiple myeloma cells
Anamika Dhyani,Adriana S. S. Duarte,João Agostinho Machado-Neto,Patricia Favaro,Patricia Favaro,Manoela M. Ortega,Sara Teresinha Olalla Saad +6 more
TL;DR: Data suggest that ANKHD1 might have a role in MM cell proliferation and cell cycle progression by regulating expression of p21, irrespective of the p53 status of the MM cell lines.
References
More filters
Book
Cancer : Principles and Practice of Oncology
TL;DR: Part I: Molecular Biology of Cancer Molecular Methods in Oncology Section 1. Amplification Techniques Section 2. RNA Interference Section 3. cDNA arrays Section 4. Tissue arrays Section 5. Cytogenetics Section 6. Bioinformatics Genomics and Proteomics Molecular Targets in oncology.
Journal ArticleDOI
Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells
Riccardo Dalla-Favera,Marco Bregni,Jan Erikson,David A. Patterson,Robert C. Gallo,Carlo M. Croce +5 more
TL;DR: Using a DNA probe that is specific for the complete gene (c-myc), different somatic cell hybrids possessing varying numbers of human chromosomes were analyzed by the Southern blotting technique and results indicate that the human c- myc gene is located on chromosome 8.
Journal ArticleDOI
Cellular Origin of Human B-Cell Lymphomas
TL;DR: The origin of human lymphomas has been studied by various approaches, including histology and immunophenotyping, but sequence analysis of the variable-region genes of B-cell lymphomas offered a molecular approach to studying the origin of the tumors.
Journal ArticleDOI
The Proto-Oncogene c-maf Is Responsible for Tissue-Specific Expression of Interleukin-4
TL;DR: The proto-oncogene c-maf, a basic region/leucine zipper transcription factor, controls tissue-specific expression of IL-4 in Th1 cells, B cells, and nonlymphoid cells and acts in synergy with the nuclear factor of activated T cells (NF-ATp) to initiate endogeneous IL- 4 production by B cells.
Journal ArticleDOI
Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.
TL;DR: It is proposed that after the t(4;14) translocation, somatic mutation during tumour progression frequently generates an FGFR3 protein that is active in the absence of ligand.
Related Papers (5)
Multiple myeloma: evolving genetic events and host interactions
Genetics and Cytogenetics of Multiple Myeloma A Workshop Report
Rafael Fonseca,Bart Barlogie,Régis Bataille,Christian Bastard,P. Leif Bergsagel,Marta Chesi,Faith E. Davies,Johannes Drach,Philip R. Greipp,Ilan R. Kirsch,W. Michael Kuehl,Jesus M. Hernandez,Stephane Minvielle,Linda M. Pilarski,John D. Shaughnessy,A. Keith Stewart,Hervé Avet-Loiseau,Hervé Avet-Loiseau +17 more